modelJ06BB08
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | StaphylococcusImmunoglobulin | |
| ATC code: | J06BB08 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 5000 | mg |
| volume of distribution: | 4.5 | L |
| clearance: | 0.21 | L/day |
| other parameters in model implementation | ||
Staphylococcus immunoglobulin is a human plasma-derived immunoglobulin G preparation enriched with antibodies to Staphylococcus aureus. It has been used for the prophylaxis and treatment of severe staphylococcal infections, especially in high-risk patients such as neonates, immunocompromised individuals, or those with extensive burns. It is not in widespread approved use in current clinical practice, with most immunoglobulins today being non-specific or targeted to other pathogens.
Pharmacokinetics
There are no published peer-reviewed sources providing detailed pharmacokinetic parameters for staphylococcus immunoglobulin in either healthy volunteers or patient populations. The following values are estimated based on typical human intravenous immunoglobulin (IVIG) pharmacokinetics.
References
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
François, B, et al., & Laterre, PF (2021). Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. The Lancet. Infectious diseases 21(9) 1313–1323. DOI:10.1016/S1473-3099(20)30995-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33894131
Weisman, LE, et al., & Mond, JJ (2009). Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. International immunopharmacology 9(5) 639–644. DOI:10.1016/j.intimp.2009.02.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19268719
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)